Skip to content

Advertisement

  • BRIEF REPORT
  • Open Access

Selecting the preferred triptans

The Journal of Headache and PainOfficial Journal of the Italian Society for the Study of Headaches5:134

https://doi.org/10.1007/s10194-004-0134-1

Received: 22 January 2004

Accepted: 26 May 2004

Abstract

The objective was to identify a subset of preferred triptans from among available agents. A criterion of dominance was applied to statistically significant differences which emerged from a recent meta-analysis of placebo-controlled trials of the oral triptans in the treatment of acute migraine. Three alternatives—almotriptan 12.5 mg, eletriptan 80 mg and rizatriptan 10 mg—emerged as nondominated. These were not only superior on an individual basis, but, taken as a group, provided statistically significant superiority over the reference product (sumatriptan 100 mg) on all 5 treatment attributes studied. However, one of these, eletriptan 80 mg, is not approved for use as first line treatment, so the subset of preferred triptans for the treatment of acute migraine therefore comprises almotriptan 12.5 mg and rizatriptan 10 mg. Thus, almotriptan 12.5 mg and rizatriptan 10 mg are the preferred agents for the treatment of acute migraine.

Key words

  • Triptans
  • Migraine
  • Dominance

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement